Task 7 Flashcards
Sample size
A sample of at least 50-100 participants per group (treatment and placebo) is a starting point.
Specific criteria for female participants
- Females with documented LOW LH levels
- Women ages between 25-40 years old (optimal fertility age)
- EXCLUDE participants with other known infertility issues
Independent variable
Administration of recombinant LH (yes vs. no/placebo)
Dependent variable
Success of ovulation
Controlled variables
- Age of participants
- Time of LH administration
How would they administer the treatment?
Recombinant LH would be administered via subcutaneous injection.
How much?
Typical doses range from 75 IU to 150 IU per injection, depending on the severity of LH deficiency.
How often?
Daily injections during the mid-to-late follicular phase (usually days 7-12 of the cycle).
Duration of the study
3-6 months per participant, allowing for several ovulation attempts
Placebo and its function
An injection that looks identical to the LH injection but contains no active ingredient. Its function is to serve as a control to compare the effectiveness of the recombinant LH.
“Chance of ovulation”
The probability that ovulation will occur in a given cycle
How is chance of ovulation measured
- Blood tests measuring progesterone levels (elevated levels confirm ovulation).
- Ultrasound to visualize the rupture of the ovarian follicle.
- Urinary LH kits might be used to confirm the LH surge that precedes ovulation.
Other factors affecting ovulation
- Lifestyle factors like diet, smoking etc
- Other medications or treatments participants may be taking
Minimization strategies
Provide diet plans, or exclude participants that undergo heavy drug use or smoking etc